|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kwa M, Makris A and Esteva FJ: Clinical
utility of gene-expression signatures in early stage breast cancer.
Nat Rev Clin Oncol. 14:595–610. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, Albain KS, André F,
Bergh J, et al Panel members, : Personalizing the treatment of
women with early breast cancer: Highlights of the St Gallen
International Expert Consensus on the Primary Therapy of Early
Breast Cancer 2013. Ann Oncol. 24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sanpaolo P, Barbieri V and Genovesi D:
Prognostic value of breast cancer subtypes on breast cancer
specific survival, distant metastases and local relapse rates in
conservatively managed early stage breast cancer: A retrospective
clinical study. Eur J Surg Oncol. 37:876–882. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Millar EK, Graham PH, O'Toole SA, McNeil
CM, Browne L, Morey AL, Eggleton S, Beretov J, Theocharous C, Capp
A, et al: Prediction of local recurrence, distant metastases, and
death after breast-conserving therapy in early-stage invasive
breast cancer using a five-biomarker panel. J Clin Oncol.
27:4701–4708. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tillett WS and Francis T: Serological
reactions in pneumonia with a non-protein somatic fraction of
pneumococcus. J Exp Med. 52:561–571. 1930. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eklund CM: Proinflammatory cytokines in
CRP baseline regulation. Adv Clin Chem. 48:111–136. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fang Y, Xu C, Wu P, Zhang LH, Li DW, Sun
JH, Li WF and Liao ZS: Prognostic role of C-reactive protein in
patients with nasopharyngeal carcinoma: A meta-analysis and
literature review. Medicine (Baltimore). 96:e84632017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zheng Z, Zhou L, Gao S, Yang Z, Yao J and
Zheng S: Prognostic role of C-reactive protein in hepatocellular
carcinoma: A systematic review and meta-analysis. Int J Med Sci.
10:653–664. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stevens L, Pathak S, Nunes QM,
Pandanaboyana S, Macutkiewicz C, Smart N and Smith AM: Prognostic
significance of pre-operative C-reactive protein and the
neutrophil-lymphocyte ratio in resectable pancreatic cancer: A
systematic review. HPB (Oxford). 17:285–291. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Woo HD, Kim K and Kim J: Association
between preoperative C-reactive protein level and colorectal cancer
survival: A meta-analysis. Cancer Causes Control. 26:1661–1670.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu Q, Gou Y, Sun C, Ding W, Xu K, Gu B,
Xia G and Ding Q: The prognostic value of C-reactive protein in
renal cell carcinoma: A systematic review and meta-analysis. Urol
Oncol. 32:50.e1–50.e8. 2014. View Article : Google Scholar
|
|
14
|
Luo Y, Fu SJ, She DL, Xiong HU and Yang
LI: Preoperative C-reactive protein as a prognostic predictor for
upper tract urothelial carcinoma: A systematic review and
meta-analysis. Mol Clin Oncol. 3:924–928. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu ZQ, Chu L, Fang JM, Zhang X, Zhao HX,
Chen YJ and Xu Q: Prognostic role of C-reactive protein in prostate
cancer: A systematic review and meta-analysis. Asian J Androl.
16:467–471. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Allin KH, Nordestgaard BG, Flyger H and
Bojesen SE: Elevated pre-treatment levels of plasma C-reactive
protein are associated with poor prognosis after breast cancer: A
cohort study. Breast Cancer Res. 13:R552011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sicking I, Edlund K, Wesbuer E, Weyer V,
Battista MJ, Lebrecht A, Solbach C, Grinberg M, Lotz J, Hoffmann G,
et al: Prognostic influence of pre-operative C-reactive protein in
node-negative breast cancer patients. PLoS One. 9:e1113062014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Frydenberg H, Thune I, Lofterød T,
Mortensen ES, Eggen AE, Risberg T, Wist EA, Flote VG, Furberg AS,
Wilsgaard T, et al: Pre-diagnostic high-sensitive C-reactive
protein and breast cancer risk, recurrence, and survival. Breast
Cancer Res Treat. 155:345–354. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Al Murri AM, Wilson C, Lannigan A, Doughty
JC, Angerson WJ, McArdle CS and McMillan DC: Evaluation of the
relationship between the systemic inflammatory response and
cancer-specific survival in patients with primary operable breast
cancer. Br J Cancer. 96:891–895. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tibau A, Ennis M and Goodwin PJ:
Post-surgical highly sensitive C-reactive protein and prognosis in
early-stage breast cancer. Breast Cancer Res Treat. 141:485–493.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Salgado R, Junius S, Benoy I, Van Dam P,
Vermeulen P, Van Marck E, Huget P and Dirix LY; Salgado R1, :
Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P and
Dirix LY: Circulating interleukin-6 predicts survival in patients
with metastatic breast cancer. Int J Cancer. 103:642–646. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Knüpfer H and Preiss R: Significance of
interleukin-6 (IL-6) in breast cancer (Review). Breast Cancer Res
Treat. 102:129–135. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dethlefsen C, Højfeldt G and Hojman P: The
role of intratumoral and systemic IL-6 in breast cancer. Breast
Cancer Res Treat. 138:657–664. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Al-Youzbaki WB, Al-Youzbaki NB and Telfah
MM: Tissue polypeptide antigen & interleukin-6: Are their serum
levels a predictor for response to chemotherapy in breast cancer?
Pak J Med Sci. 30:1108–1112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ravishankaran P and Karunanithi R:
Clinical significance of preoperative serum interleukin-6 and
C-reactive protein level in breast cancer patients. World J Surg
Oncol. 9:182011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Babaei Z, Moslemi D, Parsian H, Khafri S,
Pouramir M and Mosapour A: Relationship of obesity with serum
concentrations of leptin, CRP and IL-6 in breast cancer survivors.
J Egypt Natl Canc Inst. 27:223–229. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Honjo Y, Nangia-Makker P, Inohara H and
Raz A: Down-regulation of galectin-3 suppresses tumorigenicity of
human breast carcinoma cells. Clin Cancer Res. 7:661–668.
2001.PubMed/NCBI
|
|
28
|
Song YK, Billiar TR and Lee YJ: Role of
galectin-3 in breast cancer metastasis: Involvement of nitric
oxide. Am J Pathol. 160:1069–1075. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nangia-Makker P, Wang Y, Raz T, Tait L,
Balan V, Hogan V and Raz A: Cleavage of galectin-3 by matrix
metalloproteases induces angiogenesis in breast cancer. Int J
Cancer. 127:2530–2541. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen C, Duckworth CA, Zhao Q, Pritchard
DM, Rhodes JM and Yu LG: Increased circulation of galectin-3 in
cancer induces secretion of metastasis-promoting cytokines from
blood vascular endothelium. Clin Cancer Res. 19:1693–1704. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Van Eckyen E: Breast tumours. TNM
classification of malignant tumours. 8th. Brieley JD, Gospodarowicz
MK and Wittekind C: John Wiley and Sons, Ltd.; West Sussex: pp.
151–158. 2017
|
|
32
|
Faggioli L, Costanzo C, Merola M,
Bianchini E, Furia A, Carsana A and Palmieri M: Nuclear factor
kappa B (NF-kappa B), nuclear factor interleukin-6 (NFIL-6 or C/EBP
beta) and nuclear factor interleukin-6 beta (NFIL6-beta or C/EBP
delta) are not sufficient to activate the endogenous interleukin-6
gene in the human breast carcinoma cell line MCF-7. Comparative
analysis with MDA-MB-231 cells, an interleukin-6-expressing human
breast carcinoma cell line. Eur J Biochem. 239:624–631. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Robinson EK, Sneige N and Grimm EA:
Correlation of interleukin 6 with interleukin 1alpha in human
mammary tumours, but not with oestrogen receptor expression.
Cytokine. 10:970–976. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fontanini G, Campani D, Roncella M,
Cecchetti D, Calvo S, Toniolo A and Basolo F: Expression of
interleukin 6 (IL-6) correlates with oestrogen receptor in human
breast carcinoma. Br J Cancer. 80:579–584. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Toi M, Inada K, Suzuki H and Tominaga T:
Tumor angiogenesis in breast cancer: Its importance as a prognostic
indicator and the association with vascular endothelial growth
factor expression. Breast Cancer Res Treat. 36:193–204. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Heer K, Kumar H, Read JR, Fox JN, Monson
JR and Kerin MJ: Serum vascular endothelial growth factor in breast
cancer: Its relation with cancer type and estrogen receptor status.
Clin Cancer Res. 7:3491–3494. 2001.PubMed/NCBI
|
|
37
|
Byrne GJ, McDowell G, Agarawal R, Sinha G,
Kumar S and Bundred NJ: Serum vascular endothelial growth factor in
breast cancer. Anticancer Res 27 (5B). 3481–3487. 2007.
|
|
38
|
Hodorowicz-Zaniewska D, Kibil W, Małek A,
Szpor J, Kulig J and Sztefko K: Evaluation of serum concentrations
of vascular endothelial growth factor (VEGF) in breast cancer
patients. Pol J Pathol. 63:255–260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Greenberg S and Rugo HS: Triple-negative
breast cancer: Role of antiangiogenic agents. Cancer J. 16:33–38.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dossus L, Jimenez-Corona A, Romieu I,
Boutron-Ruault MC, Boutten A, Dupré T, Fagherazzi G,
Clavel-Chapelon F and Mesrine S: C-reactive protein and
postmenopausal breast cancer risk: Results from the E3N cohort
study. Cancer Causes Control. 25:533–539. 2014. View Article : Google Scholar : PubMed/NCBI
|
